A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue

CONCLUSIONS: Our results demonstrate that E17241 regulates glucolipid metabolism in KKAy diabetic mice while having cardiorenal benefits without inducing weight gain. It is a promising drug candidate for the treatment of T2DM.PMID:38308968 | DOI:10.1016/j.biopha.2024.116220

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 3, 2024 Category: Drugs & Pharmacology Authors: Ren Sheng Yining Li Yexiang Wu Chang Liu Weizhi Wang Xiaowan Han Yinghong Li Lijuan Lei Xinhai Jiang Yuyan Zhang Yuhao Zhang Shunwang Li Bin Hong Chao Liu Yanni Xu Shuyi Si Source Type: research